. Author manuscript; available in PMC: 2022 Jan 27.

Published in final edited form as: Int Immunopharmacol. 2019 Dec 25;79:106093. doi: 10.1016/j.intimp.2019.106093

Table 1.

Participant demographic and clinical characteristics.

		Untreated	Risperidone Treated
Total (n)		11	11
Age (M ± SD)		38.82 ± 13.91	43.27 ± 14.37
Female (n)		5	6
Male (n)		6	5
Race^*	Caucasian, non-Hispanic (n)	4	0
	Black, non-Hispanic (n)	5	10
	Asian or other Pacific Islander (n)	0	1
	Hispanic (n)	2	0
BMI (M ± SD)^*		26.02 ± 5.51	34.05 ± 9.05
Illness Duration (M ± SD)		17.82 ± 16.32	18.36 ± 15.28
Illness Status	Inpatient (n)	5	3
Illness Status	Outpatient (n)	6	8
PANSS	Positive (M ± SD)	23.81 ± 4.31	26.64 ± 5.33
	Negative (M ± SD)	16.09 ± 7.35	20.82 ± 6.49
	General (M ± SD)	43.73 ± 7.46	43.45 ± 7.03
JAK-STAT1 Composite Score (M ± SD)		−1.35 ± 1.73	.70 ± 3.15

p<.05 comparison of untreated participants with risperidone treated participants. M=mean, SD=standard deviation.